Antonio De Luca, Alessandro Folgheraiter, Thomas Caiffa, Aldostefano Porcari, Matteo Cameli, Eustachio Agricola, Maurizio Cusmà Piccione, Roberta Manganaro, Andrea Barison, Giancarlo Todiere, Giuseppe Palmiero, Gianluca Di Bella, Marco Merlo, Gianfranco Sinagra, Scipione Carerj, Concetta Zito, This Document was Promoted by Members of the 2024-2026 SIECVI Scientific Documents Committee and Reviewed by, Ilaria Caso, Antonella Moreo, Mauro Pepi, 2024-2026 SIECVI Board
Left ventricular hypertrophy (LVH) is defined by increased left ventricular wall thickness and/or mass and reflects a heterogeneous spectrum of primary myocardial diseases or an adaptive response to pressure or volume overload. Multimodality imaging, integrated with comprehensive clinical assessment, electrocardiography, and laboratory testing, plays a central role in the noninvasive evaluation of LVH [Graphical Abstract]. Echocardiography represents the first-line imaging modality for initial assessment and serial follow-up, providing comprehensive structural and functional information. Cardiac magnetic resonance imaging provides diagnostic confirmation and enables etiologic differentiation through advanced tissue characterization. Other imaging modalities, particularly nuclear medicine techniques, are employed in specific clinical contexts such as the evaluation of cardiac amyloidosis.